nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—CYP1A2—Carmustine—lymphatic system cancer	0.27	0.471	CbGbCtD
Cyclobenzaprine—CYP3A4—Cytarabine—lymphatic system cancer	0.0964	0.168	CbGbCtD
Cyclobenzaprine—CYP3A4—Teniposide—lymphatic system cancer	0.095	0.166	CbGbCtD
Cyclobenzaprine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0664	0.116	CbGbCtD
Cyclobenzaprine—CYP3A4—Vincristine—lymphatic system cancer	0.0457	0.0798	CbGbCtD
Cyclobenzaprine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00139	0.00326	CcSEcCtD
Cyclobenzaprine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00139	0.00325	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00138	0.00324	CcSEcCtD
Cyclobenzaprine—Stomatitis—Carmustine—lymphatic system cancer	0.00138	0.00324	CcSEcCtD
Cyclobenzaprine—Rash—Mechlorethamine—lymphatic system cancer	0.00138	0.00322	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00137	0.00322	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00137	0.00322	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00137	0.0032	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00136	0.00319	CcSEcCtD
Cyclobenzaprine—Anorexia—Fludarabine—lymphatic system cancer	0.00135	0.00316	CcSEcCtD
Cyclobenzaprine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00135	0.00315	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00133	0.00313	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00133	0.00311	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Vincristine—lymphatic system cancer	0.00133	0.00311	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00133	0.0031	CcSEcCtD
Cyclobenzaprine—Stomatitis—Vincristine—lymphatic system cancer	0.00132	0.00309	CcSEcCtD
Cyclobenzaprine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00132	0.00309	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00132	0.00308	CcSEcCtD
Cyclobenzaprine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0013	0.00305	CcSEcCtD
Cyclobenzaprine—Sweating—Vincristine—lymphatic system cancer	0.0013	0.00304	CcSEcCtD
Cyclobenzaprine—Nausea—Mechlorethamine—lymphatic system cancer	0.0013	0.00304	CcSEcCtD
Cyclobenzaprine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00129	0.00303	CcSEcCtD
Cyclobenzaprine—Alopecia—Bleomycin—lymphatic system cancer	0.00129	0.00302	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00129	0.00302	CcSEcCtD
Cyclobenzaprine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00129	0.00301	CcSEcCtD
Cyclobenzaprine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00129	0.00301	CcSEcCtD
Cyclobenzaprine—Urticaria—Teniposide—lymphatic system cancer	0.00128	0.00299	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Teniposide—lymphatic system cancer	0.00127	0.00298	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00127	0.00297	CcSEcCtD
Cyclobenzaprine—Hallucination—Carmustine—lymphatic system cancer	0.00127	0.00297	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00127	0.00297	CcSEcCtD
Cyclobenzaprine—Sweating—Mitoxantrone—lymphatic system cancer	0.00126	0.00296	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00126	0.00295	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00124	0.00291	CcSEcCtD
Cyclobenzaprine—Dysarthria—Methotrexate—lymphatic system cancer	0.00124	0.00291	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00123	0.00288	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00123	0.00288	CcSEcCtD
Cyclobenzaprine—Fatigue—Fludarabine—lymphatic system cancer	0.00122	0.00285	CcSEcCtD
Cyclobenzaprine—Hallucination—Vincristine—lymphatic system cancer	0.00121	0.00283	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00121	0.00283	CcSEcCtD
Cyclobenzaprine—Constipation—Fludarabine—lymphatic system cancer	0.00121	0.00283	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00119	0.00278	CcSEcCtD
Cyclobenzaprine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00118	0.00277	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00118	0.00276	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00117	0.00275	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00116	0.00273	CcSEcCtD
Cyclobenzaprine—Asthenia—Teniposide—lymphatic system cancer	0.00115	0.0027	CcSEcCtD
Cyclobenzaprine—Malaise—Bleomycin—lymphatic system cancer	0.00115	0.00268	CcSEcCtD
Cyclobenzaprine—Pruritus—Teniposide—lymphatic system cancer	0.00114	0.00267	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Carmustine—lymphatic system cancer	0.00114	0.00266	CcSEcCtD
Cyclobenzaprine—Leukopenia—Bleomycin—lymphatic system cancer	0.00114	0.00266	CcSEcCtD
Cyclobenzaprine—Alopecia—Carmustine—lymphatic system cancer	0.00113	0.00264	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Teniposide—lymphatic system cancer	0.0011	0.00258	CcSEcCtD
Cyclobenzaprine—Myalgia—Bleomycin—lymphatic system cancer	0.00108	0.00253	CcSEcCtD
Cyclobenzaprine—Chest pain—Bleomycin—lymphatic system cancer	0.00108	0.00253	CcSEcCtD
Cyclobenzaprine—Alopecia—Vincristine—lymphatic system cancer	0.00107	0.00252	CcSEcCtD
Cyclobenzaprine—Discomfort—Bleomycin—lymphatic system cancer	0.00107	0.0025	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00106	0.00248	CcSEcCtD
Cyclobenzaprine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00105	0.00246	CcSEcCtD
Cyclobenzaprine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00105	0.00245	CcSEcCtD
Cyclobenzaprine—Confusional state—Bleomycin—lymphatic system cancer	0.00105	0.00245	CcSEcCtD
Cyclobenzaprine—Vision blurred—Carmustine—lymphatic system cancer	0.00104	0.00245	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00104	0.00244	CcSEcCtD
Cyclobenzaprine—Tremor—Carmustine—lymphatic system cancer	0.00104	0.00243	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00104	0.00243	CcSEcCtD
Cyclobenzaprine—Oedema—Bleomycin—lymphatic system cancer	0.00104	0.00243	CcSEcCtD
Cyclobenzaprine—Vomiting—Teniposide—lymphatic system cancer	0.00102	0.0024	CcSEcCtD
Cyclobenzaprine—Agitation—Carmustine—lymphatic system cancer	0.00102	0.00239	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00101	0.00238	CcSEcCtD
Cyclobenzaprine—Asthenia—Fludarabine—lymphatic system cancer	0.00101	0.00238	CcSEcCtD
Cyclobenzaprine—Rash—Teniposide—lymphatic system cancer	0.00101	0.00238	CcSEcCtD
Cyclobenzaprine—Dermatitis—Teniposide—lymphatic system cancer	0.00101	0.00237	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00101	0.00236	CcSEcCtD
Cyclobenzaprine—Headache—Teniposide—lymphatic system cancer	0.00101	0.00236	CcSEcCtD
Cyclobenzaprine—Pruritus—Fludarabine—lymphatic system cancer	0.001	0.00234	CcSEcCtD
Cyclobenzaprine—Leukopenia—Carmustine—lymphatic system cancer	0.000992	0.00232	CcSEcCtD
Cyclobenzaprine—Anorexia—Bleomycin—lymphatic system cancer	0.000988	0.00231	CcSEcCtD
Cyclobenzaprine—Agitation—Vincristine—lymphatic system cancer	0.000972	0.00228	CcSEcCtD
Cyclobenzaprine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000971	0.00227	CcSEcCtD
Cyclobenzaprine—Hypotension—Bleomycin—lymphatic system cancer	0.000968	0.00227	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000967	0.00227	CcSEcCtD
Cyclobenzaprine—Convulsion—Carmustine—lymphatic system cancer	0.00096	0.00225	CcSEcCtD
Cyclobenzaprine—Hypertension—Carmustine—lymphatic system cancer	0.000957	0.00224	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000956	0.00224	CcSEcCtD
Cyclobenzaprine—Nausea—Teniposide—lymphatic system cancer	0.000955	0.00224	CcSEcCtD
Cyclobenzaprine—Vertigo—Vincristine—lymphatic system cancer	0.000951	0.00223	CcSEcCtD
Cyclobenzaprine—Leukopenia—Vincristine—lymphatic system cancer	0.000947	0.00222	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000944	0.00221	CcSEcCtD
Cyclobenzaprine—Myalgia—Carmustine—lymphatic system cancer	0.000944	0.00221	CcSEcCtD
Cyclobenzaprine—Chest pain—Carmustine—lymphatic system cancer	0.000944	0.00221	CcSEcCtD
Cyclobenzaprine—Anxiety—Carmustine—lymphatic system cancer	0.00094	0.0022	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000931	0.00218	CcSEcCtD
Cyclobenzaprine—Malaise—Mitoxantrone—lymphatic system cancer	0.000929	0.00218	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000924	0.00216	CcSEcCtD
Cyclobenzaprine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000922	0.00216	CcSEcCtD
Cyclobenzaprine—Convulsion—Vincristine—lymphatic system cancer	0.000917	0.00215	CcSEcCtD
Cyclobenzaprine—Hypertension—Vincristine—lymphatic system cancer	0.000914	0.00214	CcSEcCtD
Cyclobenzaprine—Confusional state—Carmustine—lymphatic system cancer	0.000912	0.00214	CcSEcCtD
Cyclobenzaprine—Oedema—Carmustine—lymphatic system cancer	0.000905	0.00212	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000901	0.00211	CcSEcCtD
Cyclobenzaprine—Myalgia—Vincristine—lymphatic system cancer	0.000901	0.00211	CcSEcCtD
Cyclobenzaprine—Vomiting—Fludarabine—lymphatic system cancer	0.000899	0.00211	CcSEcCtD
Cyclobenzaprine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000893	0.00209	CcSEcCtD
Cyclobenzaprine—Rash—Fludarabine—lymphatic system cancer	0.000891	0.00209	CcSEcCtD
Cyclobenzaprine—Dermatitis—Fludarabine—lymphatic system cancer	0.00089	0.00209	CcSEcCtD
Cyclobenzaprine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00089	0.00208	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000886	0.00207	CcSEcCtD
Cyclobenzaprine—Headache—Fludarabine—lymphatic system cancer	0.000886	0.00207	CcSEcCtD
Cyclobenzaprine—Tachycardia—Carmustine—lymphatic system cancer	0.000883	0.00207	CcSEcCtD
Cyclobenzaprine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000877	0.00206	CcSEcCtD
Cyclobenzaprine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000877	0.00206	CcSEcCtD
Cyclobenzaprine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000874	0.00205	CcSEcCtD
Cyclobenzaprine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00087	0.00204	CcSEcCtD
Cyclobenzaprine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000867	0.00203	CcSEcCtD
Cyclobenzaprine—Oedema—Vincristine—lymphatic system cancer	0.000864	0.00202	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000864	0.00202	CcSEcCtD
Cyclobenzaprine—Anorexia—Carmustine—lymphatic system cancer	0.000862	0.00202	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000854	0.002	CcSEcCtD
Cyclobenzaprine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000853	0.002	CcSEcCtD
Cyclobenzaprine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000848	0.00199	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000846	0.00198	CcSEcCtD
Cyclobenzaprine—Hypotension—Carmustine—lymphatic system cancer	0.000845	0.00198	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000841	0.00197	CcSEcCtD
Cyclobenzaprine—Oedema—Mitoxantrone—lymphatic system cancer	0.000841	0.00197	CcSEcCtD
Cyclobenzaprine—Nausea—Fludarabine—lymphatic system cancer	0.00084	0.00197	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000835	0.00196	CcSEcCtD
Cyclobenzaprine—Shock—Mitoxantrone—lymphatic system cancer	0.000827	0.00194	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000824	0.00193	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000824	0.00193	CcSEcCtD
Cyclobenzaprine—Urticaria—Bleomycin—lymphatic system cancer	0.000823	0.00193	CcSEcCtD
Cyclobenzaprine—Anorexia—Vincristine—lymphatic system cancer	0.000823	0.00193	CcSEcCtD
Cyclobenzaprine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000821	0.00192	CcSEcCtD
Cyclobenzaprine—Insomnia—Carmustine—lymphatic system cancer	0.000818	0.00192	CcSEcCtD
Cyclobenzaprine—Irritability—Methotrexate—lymphatic system cancer	0.000814	0.00191	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000813	0.0019	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Carmustine—lymphatic system cancer	0.000812	0.0019	CcSEcCtD
Cyclobenzaprine—Hypotension—Vincristine—lymphatic system cancer	0.000807	0.00189	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Carmustine—lymphatic system cancer	0.000807	0.00189	CcSEcCtD
Cyclobenzaprine—Somnolence—Carmustine—lymphatic system cancer	0.000804	0.00188	CcSEcCtD
Cyclobenzaprine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000802	0.00188	CcSEcCtD
Cyclobenzaprine—Ataxia—Methotrexate—lymphatic system cancer	0.000802	0.00188	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000787	0.00184	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Carmustine—lymphatic system cancer	0.000786	0.00184	CcSEcCtD
Cyclobenzaprine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000786	0.00184	CcSEcCtD
Cyclobenzaprine—Insomnia—Vincristine—lymphatic system cancer	0.000781	0.00183	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Vincristine—lymphatic system cancer	0.000776	0.00182	CcSEcCtD
Cyclobenzaprine—Constipation—Carmustine—lymphatic system cancer	0.000774	0.00181	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000766	0.00179	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000764	0.00179	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000755	0.00177	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Vincristine—lymphatic system cancer	0.000751	0.00176	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00075	0.00176	CcSEcCtD
Cyclobenzaprine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000748	0.00175	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000746	0.00175	CcSEcCtD
Cyclobenzaprine—Fatigue—Vincristine—lymphatic system cancer	0.000745	0.00174	CcSEcCtD
Cyclobenzaprine—Asthenia—Bleomycin—lymphatic system cancer	0.000744	0.00174	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00074	0.00173	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00074	0.00173	CcSEcCtD
Cyclobenzaprine—Constipation—Vincristine—lymphatic system cancer	0.000739	0.00173	CcSEcCtD
Cyclobenzaprine—Pruritus—Bleomycin—lymphatic system cancer	0.000733	0.00172	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000731	0.00171	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00073	0.00171	CcSEcCtD
Cyclobenzaprine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000725	0.0017	CcSEcCtD
Cyclobenzaprine—Constipation—Mitoxantrone—lymphatic system cancer	0.000719	0.00168	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Carmustine—lymphatic system cancer	0.000715	0.00168	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000706	0.00165	CcSEcCtD
Cyclobenzaprine—Pancytopenia—Methotrexate—lymphatic system cancer	0.0007	0.00164	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000693	0.00162	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000688	0.00161	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000685	0.0016	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Vincristine—lymphatic system cancer	0.000683	0.0016	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000679	0.00159	CcSEcCtD
Cyclobenzaprine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000668	0.00157	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000667	0.00156	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000665	0.00156	CcSEcCtD
Cyclobenzaprine—Vomiting—Bleomycin—lymphatic system cancer	0.000659	0.00154	CcSEcCtD
Cyclobenzaprine—Drowsiness—Methotrexate—lymphatic system cancer	0.000657	0.00154	CcSEcCtD
Cyclobenzaprine—Rash—Bleomycin—lymphatic system cancer	0.000654	0.00153	CcSEcCtD
Cyclobenzaprine—Dermatitis—Bleomycin—lymphatic system cancer	0.000653	0.00153	CcSEcCtD
Cyclobenzaprine—Asthenia—Carmustine—lymphatic system cancer	0.000649	0.00152	CcSEcCtD
Cyclobenzaprine—Stomatitis—Methotrexate—lymphatic system cancer	0.00064	0.0015	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000636	0.00149	CcSEcCtD
Cyclobenzaprine—Sweating—Methotrexate—lymphatic system cancer	0.00063	0.00148	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00062	0.00145	CcSEcCtD
Cyclobenzaprine—Asthenia—Vincristine—lymphatic system cancer	0.00062	0.00145	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Carmustine—lymphatic system cancer	0.000619	0.00145	CcSEcCtD
Cyclobenzaprine—Nausea—Bleomycin—lymphatic system cancer	0.000616	0.00144	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000613	0.00144	CcSEcCtD
Cyclobenzaprine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000603	0.00141	CcSEcCtD
Cyclobenzaprine—Dizziness—Carmustine—lymphatic system cancer	0.000598	0.0014	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Vincristine—lymphatic system cancer	0.000591	0.00138	CcSEcCtD
Cyclobenzaprine—Hepatitis—Methotrexate—lymphatic system cancer	0.00059	0.00138	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000585	0.00137	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000575	0.00135	CcSEcCtD
Cyclobenzaprine—Vomiting—Carmustine—lymphatic system cancer	0.000575	0.00135	CcSEcCtD
Cyclobenzaprine—Dizziness—Vincristine—lymphatic system cancer	0.000571	0.00134	CcSEcCtD
Cyclobenzaprine—Rash—Carmustine—lymphatic system cancer	0.00057	0.00134	CcSEcCtD
Cyclobenzaprine—Dermatitis—Carmustine—lymphatic system cancer	0.00057	0.00133	CcSEcCtD
Cyclobenzaprine—Headache—Carmustine—lymphatic system cancer	0.000567	0.00133	CcSEcCtD
Cyclobenzaprine—Tinnitus—Methotrexate—lymphatic system cancer	0.00055	0.00129	CcSEcCtD
Cyclobenzaprine—Vomiting—Vincristine—lymphatic system cancer	0.000549	0.00129	CcSEcCtD
Cyclobenzaprine—Rash—Vincristine—lymphatic system cancer	0.000545	0.00128	CcSEcCtD
Cyclobenzaprine—Dermatitis—Vincristine—lymphatic system cancer	0.000544	0.00127	CcSEcCtD
Cyclobenzaprine—Headache—Vincristine—lymphatic system cancer	0.000541	0.00127	CcSEcCtD
Cyclobenzaprine—Nausea—Carmustine—lymphatic system cancer	0.000537	0.00126	CcSEcCtD
Cyclobenzaprine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000535	0.00125	CcSEcCtD
Cyclobenzaprine—Rash—Mitoxantrone—lymphatic system cancer	0.00053	0.00124	CcSEcCtD
Cyclobenzaprine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00053	0.00124	CcSEcCtD
Cyclobenzaprine—Headache—Mitoxantrone—lymphatic system cancer	0.000527	0.00123	CcSEcCtD
Cyclobenzaprine—Alopecia—Methotrexate—lymphatic system cancer	0.000521	0.00122	CcSEcCtD
Cyclobenzaprine—Nausea—Vincristine—lymphatic system cancer	0.000513	0.0012	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000503	0.00118	CcSEcCtD
Cyclobenzaprine—Nausea—Mitoxantrone—lymphatic system cancer	0.0005	0.00117	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—lymphatic system cancer	0.000484	0.00113	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000476	0.00112	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—lymphatic system cancer	0.000463	0.00108	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—lymphatic system cancer	0.000461	0.00108	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—lymphatic system cancer	0.00046	0.00108	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—lymphatic system cancer	0.000445	0.00104	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—lymphatic system cancer	0.000437	0.00102	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—lymphatic system cancer	0.000437	0.00102	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—lymphatic system cancer	0.000432	0.00101	CcSEcCtD
Cyclobenzaprine—Confusional state—Methotrexate—lymphatic system cancer	0.000423	0.00099	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000419	0.000982	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00041	0.000961	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000405	0.000949	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—lymphatic system cancer	0.000399	0.000936	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—lymphatic system cancer	0.000392	0.000917	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000382	0.000894	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—lymphatic system cancer	0.000379	0.000888	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000376	0.000881	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000374	0.000875	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—lymphatic system cancer	0.000373	0.000873	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000369	0.000864	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000364	0.000853	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—lymphatic system cancer	0.000361	0.000846	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000345	0.000809	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000343	0.000803	CcSEcCtD
Cyclobenzaprine—Urticaria—Methotrexate—lymphatic system cancer	0.000333	0.00078	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000331	0.000776	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000309	0.000723	CcSEcCtD
Cyclobenzaprine—Asthenia—Methotrexate—lymphatic system cancer	0.000301	0.000704	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—lymphatic system cancer	0.000296	0.000694	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000287	0.000672	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—lymphatic system cancer	0.000277	0.000649	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—lymphatic system cancer	0.000266	0.000624	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—lymphatic system cancer	0.000264	0.000619	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—lymphatic system cancer	0.000264	0.000618	CcSEcCtD
Cyclobenzaprine—Headache—Methotrexate—lymphatic system cancer	0.000263	0.000615	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—lymphatic system cancer	0.000249	0.000583	CcSEcCtD
